In vivo fluence rate effect in photodynamic therapy of early cancers with tetra(m-hydroxyphenyl)chlorin1

Détails

ID Serval
serval:BIB_D58B9E4D7A47
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
In vivo fluence rate effect in photodynamic therapy of early cancers with tetra(m-hydroxyphenyl)chlorin1
Périodique
Photochemistry and Photobiology
Auteur(s)
Blant  S. A., Woodtli  A., Wagnieres  G., Fontolliet  C., van den  B. H., Monnier  P.
ISSN
0031-8655 (Print)
Statut éditorial
Publié
Date de publication
1996
Volume
64
Numéro
6
Pages
963-968
Notes
PT - Journal Article PT - Research Support, Non-U.S. Gov't
Résumé
Several parameters affect clinical trials in photodynamic therapy and influence the therapeutic outcome. Beside drug dose, light dose, drug-light interval and other variables, the fluence rate is a parameter that can influence the therapeutic results. In this study we have evaluated the fluence rate effect with a second-generation photosensitizer, tetra(m-hydroxyphenyl)chlorin (mTHPC) using a 7,12-dimethylbenz(a)anthracene induced early squamous cell carcinoma of the Syrian hamster cheek pouch as a tumor model. Following injection of 0.5 mg/kg of mTHPC, irradiation tests were performed at two drug-light intervals, 4 and 8 days. Wavelength and light dose were adapted from those applied routinely in clinical trials. Irradiations at 652 nm were carried out with fluences ranging from 8 to 20 J/cm2 delivered at fluence rates of 15 and 150 mW/cm2. Similar tests were also performed at 514 nm with a fluence of 80 J/cm2 delivered at fluence rates ranging from 25 to 125 mW/cm2. At both wavelengths and drug-light intervals for a given fluence, the higher fluence rates resulted in less tissue damage in tumor and healthy mucosae. However, the lower fluence rates yielded slightly less therapeutic selectivity. This study confirms that the fluence rate is of major importance in clinical PDT
Mots-clé
Animals/Carcinoma,Squamous Cell/drug therapy/Cricetinae/Mesocricetus/Mesoporphyrins/therapeutic use/Mouth Neoplasms/Neoplasms,Experimental/Photochemotherapy/Radiation-Sensitizing Agents
Pubmed
Web of science
Création de la notice
29/01/2008 19:34
Dernière modification de la notice
20/08/2019 16:55
Données d'usage